Suppression of allergen-induced airway inflammation and immune response by the peroxisome proliferator-activated receptor-alpha agonist fenofibrate

European Journal of Pharmacology

Volumn 581, Issue 1-2, 2008, Pages 177-184

  Delayre Orthez, Carine ^a   Becker, Julien ^a   Auwerx, Johan ^b,c   Frossard, Nelly ^a   Pons, Françoise ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c INSTITUT CLINIQUE DE LA SOURIS   (France)

Author keywords

Allergy; Asthma; Fenofibrate; Inflammation; PPAR

Indexed keywords

ALLERGEN; CYTOKINE; FENOFIBRATE; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; INTERLEUKIN 5; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; OVALBUMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; C57BL 6 MOUSE; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; EOSINOPHIL; IMMUNE RESPONSE; KNOCKOUT MOUSE; LUNG LAVAGE; LUNG PARENCHYMA; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; SENSITIZATION; TH1 CELL;

EID: 38749122063     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.11.040     Document Type: Article

References (27)

1. Barnes P.J. Pathophysiology of asthma. Br. J. Clin. Pharmacol. 42 (1996) 3-10
2. Barnes P.J. Corticosteroids: the drugs to beat. Eur. J. Pharmacol. 533 (2006) 2-14
3. Barnes P.J., and Adcock I.M. NF-kappa B: a pivotal role in asthma and a new target for therapy. Trends Pharmacol. Sci. 18 (1997) 46-50
4. Barnes P.J., Chung K.F., and Page C.P. Inflammatory mediators of asthma: an update. Pharmacol. Rev. 50 (1998) 515-596
5. Becker J., Delayre-Orthez C., Frossard N., and Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?. Fumdam. Clin. Pharmacol. 20 (2006) 429-447
6. Belvisi M.G., Hele D.J., and Birrell M.A. New anti-inflammatory therapies and targets for asthma and chronic obstructive pulmonary disease. Expert. Opin. Ther. Targets 8 (2004) 265-285
7. Chinetti G., Griglio S., Antonucci M., Torra I.P., Delerive P., Majd Z., Fruchart J.C., Chapman J., Najib J., and Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273 (1998) 25573-25580
8. Delayre-Orthez C., de Blay F., Frossard N., and Pons F. Dose-dependent effects of endotoxins on allergen sensitization and challenge in the mouse. Clin. Exp. Allergy 34 (2004) 1789-1795
9. Delayre-Orthez C., Becker J., Guenon I., Lagente V., Auwerx J., Frossard N., and Pons F. PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir. Res. 6 (2005) 91-101
10. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., and Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274 (1999) 32048-32054
11. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (1999) 649-688
12. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., and Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384 (1996) 39-43
13. Duez H., Chao Y.S., Hernandez M., Torpier G., Poulain P., Mundt S., Mallat Z., Teissier E., Burton C.A., Tedgui A., Fruchart J.C., Fievet C., Wright S.D., and Staels B. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J. Biol. Chem. 277 (2002) 48051-48057
14. Francis G.A., Fayard E., Picard F., and Auwerx J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65 (2003) 261-311
15. Jones D.C., Ding X., and Daynes R.A. Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J. Biol. Chem. 277 (2002) 6838-6845
16. Larche M., Robinson D.S., and Kay A.B. The role of T lymphocytes in the pathogenesis of asthma. J. Allergy Clin. Immunol. 111 (2003) 450-463 quiz 464
17. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., and Gonzalez F.J. Targeted disruption of the alpha isoform of the peroxisome proliferator - activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15 (1995) 3012-3022
18. Madej A., Okopien B., Kowalski J., Zielinski M., Wysocki J., Szygula B., Kalina Z., and Herman Z.S. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int. J. Clin. Pharmacol. Ther. 36 (1998) 345-349
19. Okamoto H., Iwamoto T., Kotake S., Momohara S., Yamanaka H., and Kamatani N. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin. Exp. Rheumatol. 23 (2005) 323-330
20. Patel H.J., Belvisi M.G., Bishop-Bailey D., Yacoub M.H., and Mitchell J.A. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J. Immunol. 170 (2003) 2663-2669
21. Rengarajan J., Szabo S.J., and Glimcher L.H. Transcriptional regulation of Th1/Th2 polarization. Immunol. Today 21 (2000) 479-483
22. Sheu M.Y., Fowler A.J., Kao J., Schmuth M., Schoonjans K., Auwerx J., Fluhr J.W., Man M.Q., Elias P.M., and Feingold K.R. Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J. Invest. Dermatol. 118 (2002) 94-101
23. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393 (1998) 790-793
24. Tanaka T., Kohno H., Yoshitani S., Takashima S., Okumura A., Murakami A., and Hosokawa M. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. 61 (2001) 2424-2428
25. Tillie-Leblond I., Pugin J., Marquette C.H., Lamblin C., Saulnier F., Brichet A., Wallaert B., Tonnel A.B., and Gosset P. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am. J. Respir. Crit. Care Med. 159 (1999) 487-494
26. Trifilieff A., Bench A., Hanley M., Bayley D., Campbell E., and Whittaker P. PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF- kappaB-independent effect. Br. J. Pharmacol. 139 (2003) 163-171
27. Woerly G., Honda K., Loyens M., Papin J.P., Auwerx J., Staels B., Capron M., and Dombrowicz D. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J. Exp. Med. 198 (2003) 411-421